We suggest that CYP26A1 plays a novel biomarker in modulating the BQ dependent pathogenic effect on the risk of oral and pharyngeal cancers (Figure S3), particularly individuals with at-risk genotype and lower expression (mRNA levels < 0.069) of CYP26A1. Here, CYP26A1 is linked to pharynx cancer.